Fast Market Research

Breast Cancer - Pipeline Review, H2 2015 - New Market Study Published

Fast Market Research announces the availability of the new Global Markets Direct report, "Breast Cancer - Pipeline Review, H2 2015", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/12/2016 -- Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2015', provides an overview of the Breast Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Get More Details on this Report and a Full Table of Contents at Breast Cancer - Pipeline Review, H2 2015

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

-The report provides a snapshot of the global therapeutic landscape of Breast Cancer
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products

Reasons to Get this Report

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Breast Cancer
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: 3-V Biosciences, Inc., 4SC AG, A&G Pharmaceutical, Inc., A. Menarini Industrie Farmaceutiche Riunite Srl, AB Science SA, AbbVie Inc., AbGenomics International, Inc., Ability Pharma, SL, Acceleron Pharma, Inc., Acetylon Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Adaptimmune Limited, ADC Therapeutics Sarl, Aduro BioTech, Inc., Advanced Cancer Therapeutics, Advanced Proteome Therapeutics Corporation, Advaxis, Inc., Advenchen Laboratories, LLC, Aegis Therapeutics, LLC, Aeglea BioTherapeutics, Inc., Aerpio Therapeutics, Inc., Aeterna Zentaris Inc., Affichem SA, Agilvax, Inc., Aileron Therapeutics, Inc., Alchemia Limited, Alethia Biotherapeutics Inc., Almac Discovery Limited, Amarna Therapeutics B.V., Ambrx, Inc., Amgen Inc., Ampio Pharmaceuticals, Inc., Amplyx Pharmaceuticals, Inc., AngioGenex, Inc., Angion Biomedica Corp., ANP Technologies, Inc., AntiCancer, Inc., Antigen Express, Inc., Antoxis Limited, Aphios Corporation, arGEN-X BV, Armour Therapeutics Inc., Arno Therapeutics, Inc., ArQule, Inc., Arrien Pharmaceuticals, LLC, Ascenta Therapeutics, Inc., Ascentage Pharma Group Corporation, Ltd., AskAt Inc., Aslan Pharmaceuticals Pte. Ltd., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, Athenex, Inc., ATLAB Pharma SAS, Atossa Genetics, Inc., Aurigene Discovery Technologies Limited, Ausio Pharmaceuticals, LLC, Axelar AB, Azaya Therapeutics, Inc., Basilea Pharmaceutica AG, Bavarian Nordic A/S, Bayer AG, BeiGene(Beijing) Co.,Ltd, BerGenBio AS, Beth Israel Deaconess Medical Center, Inc., Bexion Pharmaceuticals, LLC., Bio-Path Holdings, Inc., BIOCAD, Biocon Limited, Bionomics Limited, Bionovis SA, BioNTech AG, Bioo Therapeutics, Biotecnol, Inc., Biotest AG, Blirt S.A., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., BriaCell Therapeutics Corp., Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Campus Technologies Freiburg GmbH, Cantex Pharmaceuticals, Inc., CASI Pharmaceuticals Inc., CEL-SCI Corporation, Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Celltrion, Inc., Celsion Corporation, Ceronco Biosciences, Cerulean Pharma, Inc., Champions Oncology, Inc., ChemoCentryx, Inc., China Grand Wuhan General Pharmaceutical Research Institute, Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co., Ltd., Clevexel Pharma SAS, Clovis Oncology, Inc., CohBar, Inc., Compliment Corporation, Corcept Therapeutics Incorporated, Cristal Therapeutics, Critical Outcome Technologies Inc., Curadev Pharma Private Limited, Curadis GmbH, Curaxys, S.L., CureFAKtor Pharmaceuticals, LLC, Curis, Inc., Cyclacel Pharmaceuticals, Inc., CytomX Therapeutics, Inc., CZ BioMed Corp, Daiichi Sankyo Company, Limited, Debiopharm International S.A., Deciphera Pharmaceuticals, LLC, DEKK-TEC, Inc., DexTech Medical AB, Digna Biotech, S.L., DiNonA Inc., DNA Therapeutics S.A., Dompe Farmaceutici S.p.A., Dongkook Pharmaceutical Co., Ltd., DormaTarg, Inc., Dr. Reddy's Laboratories Limited, Egenix, Inc., EirGenix Inc., Eisai Co., Ltd., Eli Lilly and Company, EndoCeutics, Inc., Endocyte, Inc., EnGeneIC Ltd, Ensol Biosciences Inc., EntreChem, S.L., EOS Biosciences, Inc., Epigen Biosciences, Inc., Epirus Biopharmaceuticals, Inc., Erytech Pharma SA, Esperance Pharmaceuticals, Inc., Etubics Corporation, Eureka Therapeutics, Inc., Evgen Pharma PLC, Exelixis, Inc., F. Hoffmann-La Roche Ltd., FibroStatin SL, FirstString Research, Inc., Forendo Pharma Limited, Fortress Biotech, Inc., G&E Herbal Biotechnology Co., Ltd., G1 Therapeutics, Inc., Galapagos NV, Galectin Therapeutics, Inc., Galena Biopharma, Inc., Galileo Research s.r.l., Ganymed Pharmaceuticals AG, Genelux Corporation, Genenta Science s.r.l., Genentech, Inc., Genor BioPharma Co., Ltd., Genoscience Pharma, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Glycotope GmbH, Green Cross Corporation, GTx, Inc., Halozyme Therapeutics, Inc., Hanmi Pharmaceuticals, Co. Ltd., Heat Biologics, Inc., HEC Pharm Co., Ltd., Helix BioPharma Corp., Hemispherx Biopharma, Inc., Hetero Drugs Limited, Histogen, Inc., Horizon Pharma Plc, Hospira, Inc., Huabo Biopharm Co., Ltd., Huperion Sarl, Hutchison MediPharma Limited, Ignyta, Inc., Ildong Pharmaceutical Co., Ltd., Immune Design Corp., ImmuneXcite, Inc., ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomedics, Inc., Immunophotonics Inc, Immunovaccine, Inc., Immupharma Plc, IMPACT Therapeutics, Inc., Imugene Limited, Inbiopro Solutions Pvt. Ltd., Incanthera Ltd., Incyte Corporation, Infinity Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Intica Biomedical, Inc., Invictus Oncology Pvt. Ltd., Io Therapeutics, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Metastatic Breast Cancer - Pipeline Review, H2 2015
-Small-Cell Lung Cancer - Pipeline Review, H2 2015
-Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2015
-Pancreatic Cancer - Pipeline Review, H2 2015
-Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015